Mode
Text Size
Log in / Sign up
N/A Completed N=3,400

Use of Oral Contraceptives (OCs) Containing Dienogest and Risk of Venous Thromboembolism

Source: ClinicalTrials.gov NCT00523614 ↗
Enrolled (actual)
3,400
Serious AEs
0.0%
Results posted
Dec 2009
Primary outcomePrimary: Risk of Venous Thromboembolism (VTE) Between Women Who Use Dienogest/Ethinylestradiol (DNG/EE) and Women Who Use Other Low-dose Combined Oral Contraceptives (COC) — 35; 106; 161; 423 Participants — p=<0.05

Summary

The objective of this study is to compare the risk of venous thromboembolism (VTE) of oral contraceptives with non-use, focusing specifically on Valette® compared to other users of low estrogen dose combined oral contraceptives.

Outcome Measures

OutcomeResultp-value
PRIMARY
Risk of Venous Thromboembolism (VTE) Between Women Who Use Dienogest/Ethinylestradiol (DNG/EE) and Women Who Use Other Low-dose Combined Oral Contraceptives (COC)
35; 106; 161; 423 <0.05 sig

Eligibility Criteria

Inclusion Criteria

  • cases: women with a venous thromboembolism who are between 15 and 49 years old
  • control: women without a venous thromboembolism diagnosis who are between 15 and 49 years old

Exclusion Criteria

  • women outside the defined age range
  • women with severe language problems
  • women who are not willing to participate
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00523614). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search